View abstract

This abstract is assigned to session OB Poster session > in poster area

Title	Healaflow® in deep sclerectomy: a retrospective study
Abstract Nr.	140

Purpose	Different implants have been used in the past to modulate the postoperative fibrosis in deep sclerectomy. Recently, a reticulated sodium hyaluronate (Healaflow®, Anteis SA) has been developed that has the potential to work as a space-filling product injected intrasclerally and subconjunctivally during deep sclerectomy. In this retrospective study the first clinical experiences were reported.
Methods	Healaflow® was applied during 20 deep sclerectomies. The types of glaucoma were primary open-angle (10), primary angle-closure (4), exfoliative (2), congenital (2), traumatic (1) and steroid induced (1). The eye pressures and anti-glaucoma medication use were recorded pre- and postoperatively as well as complications, aspect of filtration bleb, postoperative management and duration of follow-up. In 9 eyes ultrasound biomicroscopy was done.
Results	The mean preoperative eye pressure was 19 mmHg (± 5.2, 12-34) under medical treatment (2.4 anti-glaucoma medications per patient, ± 1.4, 0-5). The mean postoperative eye pressure at the last follow-up was 12.4 mmHg (±3.6, 6-20) with a mean follow-up of 25.8 weeks (± 14.4, 4-52). Six patients were on a pressure reducing medication postoperatively. In 8 patients needling with mitomycine C injection was necessary. Ultrasound biomicroscopy demonstrated a prominent subconjunctival bleb and an easily visible intrascleral canal in respectively 7 and 5 patients.
Conclusion	Healaflow® seems to be a promising aid in the management of the fibrosis process following deep sclerectomy surgery. A prospective multi-centre study in Switzerland is planned.

Author 1

Last name	DE SMEDT
Initials	S
Department	Centre du Glaucome, Clinique Montchoisi
City	Lausanne

Author 2

Last name	Mermoud
Initials	A
Department	Centre du Glaucome, Clinique Montchoisi
City	Lausanne